This guidance updates and replaces NICE technology appraisal guidance on dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal; TA648). Next review: This guidance will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results